EP Patent

EP4066826A1 — Retinoic acid receptor gamma agonists for muscle repair and regeneration

Assigned to Thomas Jefferson University · Expires 2022-10-05 · 4y expired

What this patent protects

The invention provides a Palovarotene (4-[(1E)-2-[5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-3-(1H-pyrazol-1-ylmethyl)-2-naphthalenyl]-ethenyl]-benzoic acid), or a pharmaceutically acceptable salt thereof, for use in a method for the treatment of a muscle damaging myopathy.

USPTO Abstract

The invention provides a Palovarotene (4-[(1E)-2-[5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-3-(1H-pyrazol-1-ylmethyl)-2-naphthalenyl]-ethenyl]-benzoic acid), or a pharmaceutically acceptable salt thereof, for use in a method for the treatment of a muscle damaging myopathy.

Drugs covered by this patent

Patent Metadata

Patent number
EP4066826A1
Jurisdiction
EP
Classification
—
Expires
2022-10-05
Drug substance claim
No
Drug product claim
No
Assignee
Thomas Jefferson University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.